The most commonly used PCSK9 inhibitors, evolocumab and alirocumab, were found to be associated with musculoskeletal and connective tissue disorders (including back pain, myalgia, pain in extremity, arthralgia, muscle spasms), in a recent retrospective study based on the Food and Drug Administration adverse event reporting system database [36]. This evidence concerns the gene PCSK9 and connective tissue disorder.